MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux
05 Julio 2024 - 11:00AM
Business Wire
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a
clinical-stage biotechnology company and a leader in the
development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
enhancing survival for patients with cancer, today announces
its half-year report on the liquidity contract with the firm Kepler
Cheuvreux and an increase of €50,000 to the resources allocated to
the contract, in accordance with the provisions of article 4 of AMF
decision no. 2021-01 of June 22, 2021.
Under the liquidity contract entered into between Maat Pharma
and Kepler Cheuvreux, the following resources appeared on the
liquidity account on June 30th, 2024:
- 26,929 shares
- € 17,089.40
- Number of executions on buy side on semester: 933
- Number of executions on sell side on semester: 1,014
- Traded volume on buy side on semester: 28,959 shares for €
237,891.32
- Traded volume on sell side on semester: 26,266 shares for €
220,168.07
As a reminder:
- the following resources appeared on the last half year
statement on December 31, 2023 on the liquidity account:
- 24,236 shares
- € 34,107.60
- Number of executions on buy side on semester: 627
- Number of executions on sell side on semester: 368
- Traded volume on buy side on semester: 18,328 shares for €
122,340.49
- Traded volume on sell side on semester: 9,576 shares for €
64,693.03
- the following resources appeared on the liquidity account when
the activity started:
Following the addition of these resources for the amount of
€50,000, the position on July 4th, 2024, is:
- 26,006 shares
- € 74,303.08
The implementation of this report is carried out in accordance
with AMF Decision N°2021-01 of June 22nd, 2021, renewing the
implementation of liquidity contracts for shares as an accepted
market practice.
Buy Side Sell Side Number ofexecutions
Number ofshares Tradedvolume inEUR Number
ofexecutions Number ofshares Tradedvolume inEUR
Total
933
28,959
237,891.32
1,014
26,266
220,168.07
02/01/2024
-
-
-
9
102
719.10
03/01/2024
3
60
448.80
15
435
3,275.55
04/01/2024
9
126
948.78
8
211
1,612.04
05/01/2024
2
45
339.30
3
90
689.40
08/01/2024
18
410
2,886.40
-
-
-
09/01/2024
11
340
2,237.20
15
425
2,843.25
10/01/2024
5
130
877.50
2
72
487.44
11/01/2024
2
2
13.74
10
241
1,679.77
12/01/2024
4
50
351.00
2
70
501.20
15/01/2024
8
203
1,408.82
8
110
779.90
16/01/2024
3
36
252.00
3
35
246.40
17/01/2024
5
70
482.30
-
-
-
18/01/2024
5
151
1,026.80
-
-
-
19/01/2024
10
222
1,469.64
1
30
201.00
22/01/2024
3
50
351.00
27
641
4,512.64
23/01/2024
-
-
-
5
93
672.39
24/01/2024
7
175
1,242.50
4
130
928.20
25/01/2024
5
71
506.94
2
36
257.76
26/01/2024
3
10
71.50
4
93
668.67
29/01/2024
7
141
1,022.25
8
155
1,148.55
30/01/2024
2
21
151.20
2
36
260.64
31/01/2024
4
110
784.30
6
148
1,061.16
01/02/2024
3
60
430.80
2
42
304.50
02/02/2024
8
160
1,142.40
8
150
1,087.50
05/02/2024
-
-
-
2
35
250.95
06/02/2024
3
70
497.00
5
105
753.90
07/02/2024
4
85
606.05
-
-
-
08/02/2024
2
21
149.94
5
83
593.45
09/02/2024
10
185
1,311.65
6
118
859.04
12/02/2024
7
127
896.62
1
1
7.22
13/02/2024
1
1
7.02
4
24
169.44
14/02/2024
4
69
481.62
2
32
227.20
15/02/2024
3
26
182.52
10
151
1,069.08
16/02/2024
2
30
213.00
3
41
293.15
19/02/2024
7
130
928.20
17
280
2,027.20
20/02/2024
-
-
-
15
329
2,470.79
21/02/2024
9
130
964.60
-
-
-
22/02/2024
-
-
-
9
115
865.95
23/02/2024
1
1
7.62
53
1,131
9,398.61
26/02/2024
26
550
4,526.50
9
103
850.78
27/02/2024
6
75
612.00
13
277
2,310.18
28/02/2024
45
880
6,758.40
23
706
5,655.06
29/02/2024
15
211
1,673.23
3
34
270.30
01/03/2024
4
90
711.00
10
200
1,606.00
04/03/2024
14
260
2,048.80
7
130
1,036.10
05/03/2024
9
162
1,263.60
10
133
1,046.71
06/03/2024
11
245
2,035.95
53
1,009
8,465.51
07/03/2024
2
20
170.40
21
260
2,236.00
08/03/2024
17
335
2,814.00
6
94
797.12
11/03/2024
7
114
992.94
22
381
3,341.37
12/03/2024
7
139
1,234.32
10
316
2,837.68
13/03/2024
1
35
315.00
25
1,039
9,735.43
14/03/2024
30
921
8,427.15
13
319
2,992.22
15/03/2024
11
291
2,697.57
28
632
5,890.24
18/03/2024
5
99
903.87
3
45
413.55
19/03/2024
-
-
-
6
74
682.28
20/03/2024
20
553
4,943.82
13
328
2,971.68
21/03/2024
8
370
3,204.20
3
55
480.70
22/03/2024
6
125
1,113.75
19
422
3,798.00
25/03/2024
12
193
1,796.83
16
481
4,540.64
26/03/2024
6
158
1,448.86
8
173
1,600.25
27/03/2024
1
50
465.00
6
258
2,414.88
28/03/2024
22
692
6,304.12
8
343
3,217.34
02/04/2024
5
185
1,626.15
6
185
1,635.40
03/04/2024
4
56
495.60
1
1
8.86
04/04/2024
-
-
-
4
90
808.20
05/04/2024
-
-
-
17
435
4,023.75
08/04/2024
9
256
2,403.84
26
626
5,959.52
09/04/2024
8
133
1,263.50
10
444
4,253.52
10/04/2024
-
-
-
7
226
2,171.86
11/04/2024
2
36
342.00
5
33
316.47
12/04/2024
2
20
189.60
1
1
9.56
15/04/2024
41
1,314
12,246.48
25
785
7,622.35
16/04/2024
4
125
1,140.00
14
325
2,996.50
17/04/2024
13
578
5,138.42
-
-
-
18/04/2024
3
101
906.98
5
266
2,420.60
19/04/2024
21
1,779
15,726.36
7
304
2,723.84
22/04/2024
4
330
2,864.40
11
593
5,200.61
23/04/2024
3
124
1,088.72
6
157
1,389.45
24/04/2024
6
217
1,907.43
2
2
17.62
25/04/2024
1
1
8.80
12
468
4,165.20
26/04/2024
2
130
1,170.00
3
29
262.74
29/04/2024
6
285
2,676.15
20
652
6,109.24
30/04/2024
6
354
3,313.44
3
105
996.45
02/05/2024
5
221
2,048.67
2
80
747.20
03/05/2024
1
1
9.24
7
264
2,460.48
06/05/2024
10
323
3,007.13
4
91
849.94
07/05/2024
4
244
2,286.28
12
466
4,385.06
08/05/2024
1
20
188.00
1
5
47.30
09/05/2024
-
-
-
1
95
898.70
10/05/2024
6
161
1,513.40
2
39
368.94
13/05/2024
2
103
968.20
2
101
952.43
14/05/2024
2
77
719.18
2
84
788.76
15/05/2024
55
3,305
27,695.90
5
150
1,281.00
16/05/2024
7
340
2,692.80
9
260
2,072.20
17/05/2024
12
387
3,154.05
15
325
2,668.25
20/05/2024
8
325
2,665.00
7
205
1,693.30
21/05/2024
7
265
2,130.60
4
200
1,624.00
22/05/2024
11
344
2,752.00
3
88
719.84
23/05/2024
3
62
494.76
6
130
1,040.00
24/05/2024
6
308
2,439.36
8
230
1,826.20
27/05/2024
1
15
119.10
2
80
640.80
28/05/2024
2
70
558.60
3
55
443.30
29/05/2024
8
212
1,704.48
5
129
1,046.19
30/05/2024
8
313
2,500.87
4
88
709.28
31/05/2024
8
451
3,598.98
1
1
8.04
03/06/2024
3
150
1,194.00
3
50
400.00
04/06/2024
6
200
1,586.00
4
110
875.60
05/06/2024
5
119
940.10
5
100
794.00
06/06/2024
7
250
1,970.00
1
1
7.94
07/06/2024
6
214
1,697.02
8
140
1,113.00
10/06/2024
9
305
2,400.35
1
40
316.80
11/06/2024
5
200
1,560.00
5
212
1,670.56
12/06/2024
3
105
807.45
1
50
385.00
13/06/2024
5
163
1,253.47
4
125
965.00
14/06/2024
17
440
3,291.20
2
57
434.91
17/06/2024
26
700
4,704.00
6
285
1,915.20
18/06/2024
3
60
403.80
7
355
2,410.45
19/06/2024
10
591
3,953.79
3
39
267.54
20/06/2024
4
68
450.84
7
150
1,009.50
21/06/2024
2
51
346.80
5
303
2,084.64
24/06/2024
1
19
131.10
7
174
1,211.04
25/06/2024
7
150
1,081.50
10
360
2,610.00
26/06/2024
-
-
-
26
944
7,174.40
27/06/2024
19
613
4,677.19
4
89
688.86
28/06/2024
23
904
6,535.92
4
187
1,357.62
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome, in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240705981889/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications Jacob VERGHESE or Desmond JAMES
+49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Maat Pharma (EU:MAAT)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024